Skip to main content
European Commission logo print header

Evolving reversible iMmunocapture by membrane sensing peptides: towARds scalable extracellular VEsicLes isolation

Descrizione del progetto

Potenziare le vescicole extracellulari per uso biomedico

Sono in corso di valutazione per finalità terapeutiche e diagnostiche le vescicole extracellulari (EV, extracellular vesicles) rilasciate dalle cellule come parte integrante della comunicazione da cellula a cellula. L’obiettivo del progetto MARVEL, finanziato dall’UE, è superare le difficoltà presentate dall’isolamento delle EV al fine di avanzare nel processo oltre il livello analitico. A tale scopo, gli scienziati impiegheranno una nuova tecnologia per l’isolamento reversibile, sviluppata in origine durante il progetto H2020 INDEX, che sarà implementata con i peptidi a rilevamento di membrana. Ciò rappresenterà un cambio di paradigma dagli anticorpi ai peptidi come classe alternativa di ligandi di affinità, caratterizzati da elevata efficienza di acquisizione delle EV. La tecnologia sarà applicata allo sviluppo di medicinali basati sulle EV per la riparazione cardiaca e alla diagnosi del cancro della vescica nei campioni di urina.

Obiettivo

Extracellular vesicles (EV) are submicron membrane vesicles released by most cells with a fundamental role in cell-to-cell communication. Much interest is flourishing towards their exploitation in regenerative medicine and diagnostics. However, the fulfilment of the EV promise is hampered by severe limitations in their isolation, characterization and manufacturing. A particularly arduous task is to move the isolation of specific EV subpopulations beyond the analytical scale and towards scalable processes. In this scenario, our project will leverage on DNA-directed reversible immunocapturing (rDDI), a new technology developed within FET-OPEN project “INDEX”. rDDI relies on the reversible EV isolation mediated by immunoaffinity followed by intact vesicles recovery upon enzymatic cleavage of a DNA linker used to anchor antibodies on solid supports. Despite unprecedented efficiency in the recovery of highly pure EVs, limitations inherent to antibodies (high costs, batch-to-batch variation and limited versatility of chemical manipulation) substantially impair the scalability of rDDI for any operating scale exceeding the analytical one. MARVEL targets a paradigm shift from antibodies to peptides as an alternative class of affinity ligands for EV capturing by introducing membrane-sensing peptides (MSP) as novel ligands for the size-selective capturing of small EV, unbiased by differential surface protein expression. MARVEL mission is to combine and implement rDDI and MSP technologies, towards the first and best performing ever affinity-based technology for scalable and reversible small EV (<200nm) isolation. The modularity in scaling-up of the novel protocols and kits will be demonstrated on medium/large sample volumes in relevant environments for therapeutic and diagnostics use of EVs and specifically: 1) In the manufacturing of GMP-grade EVs as a medicinal product for cardiac repair; 2) In urine-based liquid biopsy for bladder cancer diagnostics.

Invito a presentare proposte

H2020-FETPROACT-2019-2020

Vedi altri progetti per questo bando

Bando secondario

H2020-EIC-FETPROACT-2019

Meccanismo di finanziamento

RIA - Research and Innovation action

Coordinatore

CONSIGLIO NAZIONALE DELLE RICERCHE
Contribution nette de l'UE
€ 773 158,75
Indirizzo
Piazzale aldo moro 7
00185 Roma
Italia

Mostra sulla mappa

Regione
Centro (IT) Lazio Roma
Tipo di attività
Research Organisations
Collegamenti
Costo totale
€ 773 158,75

Partecipanti (6)